ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. ACROBiosystems established long-term collaborations with big pharma like Pfizer, Novartis, and Johnson & Johnson, and well-known academic institutes.
To fight against COVID‑19, ACROBiosystems has been keeping a close eye on the continuing pandemic and is accelerating the development of SARS‑CoV‑2 protein antigens, antibodies, kits, and other related products to facilitate the development of serologic tests, therapeutic antibodies, and vaccines.
As the viruses is constantly mutating, new variants are expected to potentially increase the transmissibility and severity of COVID-19. ACROBiosystems is going full steam ahead on developing a collection of recombinant antigens for these emerging variants. The reagents can rapidly assess the efficacy of existing therapeutics and vaccines against the variants and enable the development of mutation-resistant antibodies and vaccine candidates/booster shots.